Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Gapping up/down: MNST 14%, AVGO +5%, JD +5%, ANF +4% and BURL +3% after earnings; SSI -25%, JUNO -7%, KR -4%, SHAK -4% and BUD -4% after earnings, metals/miners showing early weakness<p><strong>Gapping up<br/> In reaction to strong earnings/guidance</strong>:</p><ul><li><strong>MNST</strong> +13.7%, <strong>ONP</strong> +10.6%, <strong>NVGS</strong> +9.1%, <strong>CWST</strong> +6.9%, <strong>FOXF</strong> +6.8%, <strong>PEIX</strong> +6.6%, <strong>BLDP</strong> +6.5%, <strong>WTI</strong> +6.1%</li><li><strong>AMRC</strong> +5.8%, <strong>GKOS</strong> +5.4%, <strong>AVGO</strong> +5.3%, <strong>SSH</strong> +5.1%, <strong>JD</strong> +4.8%, <strong>ANF</strong> +4.5%, <strong>HIIQ</strong> +3.6%, <strong>BURL</strong> +3.2%, <strong>EPE</strong> +3.1%</li><li><strong>ALIM</strong> +3%, <strong>ANW</strong> +2.9%, <strong>HDSN</strong> +2.4%, <strong>ASM</strong> +2.3%, <strong>WSR</strong> +2.1%, <strong>ACIW</strong> +2%, <strong>AJRD</strong> +1.9%, <strong>JCAP</strong> +1.1%</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>AUPH</strong> +65.2% (announces its Phase IIb AURA-LV study in lupus nephritis met the complete and partial remission («CR»/ «PR») endpoints at 48 weeks; AURORA Phase III trial with low dose voclosporin on track to commence in 2Q17)</li><li><strong>ALQA</strong> +12.7% ( Celgene [CELG] increases active stake to 22.2% (Prior 15.9%) — Celgene purchased 4 mln shares in ALQA's 2/27 private placement)</li><li><strong>VRML</strong> +10.6% (announces a contracted agreement with Blue Cross Blue Shield of Michigan for OVA1)</li><li><strong>EXAS</strong> +7.7% (EXACT Sciences and Mayo Clinic study shows promise of new blood-based lung cancer test),</li><li><strong>KAO</strong> +2.5% (reviews its R&D Day agenda; Plazomicin NDA submission planned for the second half of 2017 )</li><li><strong>CAMT</strong> +2.5% ( announces that 'one of the world's leading CMOS Image Sensor manufacturers' placed multiple orders for inspection and metrology systems)</li><li><strong>VRX</strong> +1.6% ( corrects 'misleading report about Salix investigation' )</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>SRPT</strong> +4.3% (upgraded to Outperform at Leerink Partners)</li><li><strong>ARMK</strong> +2.7% (added to Conviction Buy List at Goldman)</li></ul><p><strong>Gapping down<br/> In reaction to disappointing earnings/guidance</strong>:</p><ul><li><strong>SSI</strong> -25%, <strong>TDOC</strong> -10.5%, <strong>RMGN</strong> -10.2%, <strong>MEI</strong> -9.8%, <strong>JUNO</strong> -7.1%, <strong>PSTG</strong> -6.9%, <strong>PLNT</strong> -6.2%, <strong>PDLI</strong> -5.7%</li><li><strong>NKTR</strong> -4.8%, <strong>OPK</strong> -4.4%, <strong>KR</strong> -4.2%, <strong>SHAK</strong> -3.8%, <strong>BUD</strong> -3.8%, <strong>RTRX</strong> -3.5%, <strong>ABEV</strong> -3.5%, <strong>VGR</strong> -2.9%, <strong>ATHM</strong> -2.1%</li><li><strong>CIO</strong> -2%, <strong>PRTK</strong> -1.7%, <strong>FSIC</strong> -1.4%, <strong>GCP</strong> -1.3%, <strong>PFMT</strong> -1.1%, <strong>BOX</strong> -1%</li></ul><p><strong>Select metals/mining stocks trading lower</strong>:</p><ul><li><strong>HMY</strong> -3.5%, <strong>MTL</strong> -3%, <strong>AU</strong> -1.8%, <strong>GFI</strong> -1.6%, <strong>ABX</strong> -1.6%</li><li><strong>GDX</strong> -1.5%, <strong>NEM</strong> -1.5%, <strong>SLW</strong> -1.3%, <strong>GOLD</strong> -1%, <strong>AG</strong> -0.9%</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>ADPT</strong> -29% (files to delay Form 10-K )</li><li><strong>PBYI</strong> -20.8% (after Roche's (RHHBY) Phase III APHINITY study for Perjeta met its primary endpoint treating breast cancer; also reported earnings)</li><li><strong>PTCT</strong> -18.5% (Ataluren Confirmatory Trial in nonsense mutation cystic fibrosis did not achieve its primary or secondary endpoints)</li><li><strong>AXTI</strong> -11.3% (prices its previously announced underwritten public offering of 4,615,385 shares of its common stock at a price to the public of $6.50/share)</li><li><strong>ARES</strong> -9.1% (commences a public offering of 7.5 mln common units representing limited partnership interests by a selling unitholder)</li><li><strong>AHP</strong> -5.8% (commences offerings of 1,150,000 shares of 5.50% Series B Cumulative Convertible Preferred Stock and 5.75 mln of its common stock)</li><li><strong>KITE</strong> -3.4% (commences 4.75 mln common stock offering; also downgraded to Neutral from Buy at Citigroup)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>AEO</strong> -0.5% (downgraded to Neutral at BofA/Merrill)</li></ul></td> </tr></table>"